Cost-effectiveness of Babesia microti antibody and nucleic acid blood donation screening using results from prospective investigational studies

Transfusion

Volumn 55, Issue 9, 2015, Pages 2256-2271

  Bish, Ebru K ^a   Moritz, Erin D ^b   El Amine, Hadi ^a   Bish, Douglas R ^a   Stramer, Susan L ^b  

^a State University   (United States)

^b Scientific Support Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BABESIA MICROTI ANTIBODY; NUCLEIC ACID; UNCLASSIFIED DRUG; PROTOZOAL DNA; PROTOZOAL RNA; PROTOZOON ANTIBODY;

ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE TRANSMISSION; ECONOMIC EVALUATION; ENDEMIC DISEASE; HUMAN; PIROPLASMOSIS; POLYMERASE CHAIN REACTION; PREVALENCE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; SCREENING TEST; SENSITIVITY ANALYSIS; BABESIA MICROTI; BIOLOGICAL MODEL; BLOOD; DONOR SELECTION; ECONOMICS; FEMALE; MALE; PROCEDURES; STATISTICAL MODEL;

ANTIBODIES, PROTOZOAN; BABESIA MICROTI; BABESIOSIS; BLOOD DONORS; DNA, PROTOZOAN; DONOR SELECTION; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, ECONOMIC; POLYMERASE CHAIN REACTION; RNA, PROTOZOAN;

EID: 84941810489     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13136     Document Type: Article

References (32)

1. Western KA, Benson GD, Gleason NN, et al., Babesiosis in a Massachusetts resident. N Engl J Med 1970; 283: 854-6.
2. Gorenflot A, Moubri K, Precigout E, et al., Human babesiosis. Ann Trop Med Parasitol 1998; 92: 489-501.
3. Ruebush T, Juranek DD, Chisholm ES, et al., Human babesiosis on Nantucket Island. Evidence for self-limited and subclinical infections. N Engl J Med 1977; 297: 825-7.
4. Hunfeld KP, Hildebrandt A, Gray J., Babesiosis: recent insights into an ancient disease. Int J Parasitol 2008; 38: 1219-37.
5. Vannier E, Gewurz BE, Krause PJ., Human babesiosis. Infect Dis Clin North Am 2008; 22: 469-88.
6. Centers for Disease Control and Prevention (CDC). Babesiosis surveillance-18 states, 2011. MMWR Morb Mortal Wkly Rep 2012; 61: 505-9.
7. Homer MJ, Aguilar-Delfin I, Telford SR, et al., Babesiosis. Clin Microbiol Rev 2000; 13: 451-69.
8. Herwaldt BL, Linden JV, Bosserman E, et al., Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med 2011; 155: 509-19.
9. Krause PJ, Gewurz BE, Hill D, et al., Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46: 371-6.
10. July 26-27, 2010: Blood Products Advisory Committee meeting presentations [Internet]. Silver Spring (MD): US Food and Drug Administration; last updated 2014 Feb 21 [cited 2014 Jul 25]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/ucm221857.htm
11. Moritz E, Johnson S, Winston C., Prospective investigational blood donation screening for Babesia microti [abstract]. Transfusion 2013: 53 (Suppl): 13A.
12. Moritz ED, Winton CS, Johnson ST, et al., Investigational screening for Babesia microti in a large repository of blood donor samples from non-endemic and endemic areas of the United States. Transfusion 2014; 54: 2226-36.
13. Simon MS, Leff JA, Pandya A, et al., Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. Transfusion 2014: 54: 889-99
14. Johnson S, Cable R, Leiby D., Lookback investigations of Babesia microti-seropositive blood donors: seven-year experience in a Babesia-endemic area. Transfusion 2012; 52: 1509-16.
15. Goodell AJ, Bloch EM, Krause PJ, et al., Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply. Transfusion 2014; 54: 2245-57.
16. Young C, Chawla A, Berardi V, et al., Preventing transfusion-transmitted babesiosis: preliminary experience of the first laboratory-based blood donor screening program. Transfusion 2012; 52: 1523-9.
17. Kessler D, Erwin J, Busch M., Serological findings in donors who are deferred for a history of babesiosis: abstracts for the AABB Annual Meeting and CTTXPO. Transfusion 2012; 52: 211.
18. White DJ, Talarico J, Chang HG, et al., Human babesiosis in New York State: review of 139 hospitalized cases and analysis of prognostic factors. Arch Intern Med 1998; 158: 2149-54.
19. Hatcher JC, Greenberg PD, Antique J, et al., Severe babesiosis in Long Island: review of 34 cases and their complications. Clin Infect Dis 2001; 32: 1117-25.
20. Tonnetti L, Eder AF, Dy B, et al., Transfusion complications: transfusion-transmitted Babesia microti identified through hemovigilance. Transfusion 2009; 49: 2557-63.
21. Joseph JT, Roy SS, Shams N, et al., Babesiosis in Lower Hudson Valley, New York, USA. Emerg Infect Dis 2011; 17: 843-7.
22. Kleinman S, Marshall D, AuBuchon J, et al., Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004; 44: 386-90.
23. Custer B, Busch MP, Marfin AA, et al., The cost-effectiveness of screening the US blood supply for West Nile virus. Ann Intern Med 2005; 143: 486-92.
24. Agapova M, Busch MP, Custer B., Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion 2010; 50: 2220-32.
25. Lavelle TA, Meltzer MI, Gebremariam A, et al., Community-based values for 2009 pandemic influenza A H1N1 illnesses and vaccination-related adverse events. PLOS One 2011; 6: e27777.
26. Angus DC, Musthafa AA, Clermont G, et al., Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163: 1389-94.
27. Healthcare Cost and Utilization Project (HCUP) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; page last reviewed 2014 Apr [cited 2014 Jul 25]. Available from: http://www.ahrq.gov/data/hcup
28. Red book [Internet]. Greenwood Village (CO): Truven Health Analytics; c2015 [accessed 2014 Jul 25]. Available from: http://www.redbook.com/redbook/online
29. Moritz ED, Stramer SL., Blood donation screening for Babesia microti: feasibility and results. ISBT Sci Ser. 2014; 10: 169 -72.
30. Moritz E, Winton C, Townsend R, et al., Extended Babesia microti investigational screening studies: implications for transfusion-transmitted babesiosis (TTB). Transfusion 2014; 54 (Suppl 2S): 26A-27.
31. Evaluating uncertainty components: type B [Internet]. Gaithersburg (MD): The National Institute of Standards and Technology (NIST); last updated 2000 Oct [accessed 2015 Feb]. Available from: http://physics.nist.gov/cuu/Uncertainty/typeb.html
32. Ness PM, Lipton KS., Selective transfusion protocols: errors and accidents waiting to happen. Transfusion 2001; 41: 713-5.